Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload in people with thalassaemia
Please note that following on from information provided to NICE by the company in June 2011, the appraisal of Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload [ID350] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 350
Referral date 01 July 2010
Topic area
  • Blood and immune system
  • Endocrine, nutritional and metabolic

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Shalu Kanal
Executive Lead: Peter Littlejohns
Project manager: Jeremy Powell
Technical Lead: Raisa Sidhu

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
24 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in June 2011, the appraisal of Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload [ID350] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

For further information on our processes and methods, please see our CHTE processes and methods manual